Next Article in Journal
Synergistic Anti-Inflammatory Activity of Apolipoprotein A-I and CIGB-258 in Reconstituted High-Density Lipoproteins (rHDL) against Acute Toxicity of Carboxymethyllysine in Zebrafish and Its Embryo
Previous Article in Journal
Bioavailability of Oral Curcumin in Systematic Reviews: A Methodological Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 2
10.3390/ph17020166
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

[18F]Fluspidine—A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System

by
Friedrich-Alexander Ludwig
1,
Erik Laurini
2,
Judith Schmidt
3,
Sabrina Pricl
2,4,
Winnie Deuther-Conrad
1 and
Bernhard Wünsch
3,5,*
1
Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Helmholtz-Zentrum Dresden-Rossendorf, D-04318 Leipzig, Germany
2
Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, University of Trieste, 34127 Trieste, Italy
3
Institut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany
4
Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-136 Lodz, Poland
5
GRK 2515, Chemical Biology of Ion Channels (Chembion), Universität Münster, Corrensstraße 48, D-48149 Münster, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(2), 166; https://doi.org/10.3390/ph17020166
Submission received: 12 December 2023 / Revised: 18 January 2024 / Accepted: 25 January 2024 / Published: 28 January 2024
(This article belongs to the Special Issue Sigma Receptors: Past, Present and Perspectives on Multiple Therapeutic Exploitations)
Browse Figures
Versions Notes

Abstract

:
σ1 receptors play a crucial role in various neurological and neurodegenerative diseases including pain, psychosis, Alzheimer’s disease, and depression. Spirocyclic piperidines represent a promising class of potent σ1 receptor ligands. The relationship between structural modifications and σ1 receptor affinity and selectivity over σ2 receptors led to the 2-fluoroethyl derivative fluspidine (2, Ki = 0.59 nM). Enantiomerically pure (S)-configured fluspidine ((S)-2) was prepared by the enantioselective reduction of the α,β-unsaturated ester 23 with NaBH4 and the enantiomerically pure co-catalyst (S,S)-24. The pharmacokinetic properties of both fluspidine enantiomers (R)-2 and (S)-2 were analyzed in vitro. Molecular dynamics simulations revealed very similar interactions of both fluspidine enantiomers with the σ1 receptor protein, with a strong ionic interaction between the protonated amino moiety of the piperidine ring and the COO- moiety of glutamate 172. The 18F-labeled radiotracers (S)-[18F]2 and (R)-[18F]2 were synthesized in automated syntheses using a TRACERlab FX FN synthesis module. High radiochemical yields and radiochemical purity were achieved. Radiometabolites were not found in the brains of mice, piglets, and rhesus monkeys. While both enantiomers revealed similar initial brain uptake, the slow washout of (R)-[18F]2 indicated a kind of irreversible binding. In the first clinical trial, (S)-[18F]2 was used to visualize σ1 receptors in the brains of patients with major depressive disorder (MDD). This study revealed an increased density of σ1 receptors in cortico-striato-(para)limbic brain regions of MDD patients. The increased density of σ1 receptors correlated with the severity of the depressive symptoms. In an occupancy study with the PET tracer (S)-[18F]2, the selective binding of pridopidine at σ1 receptors in the brain of healthy volunteers and HD patients was shown.

1. Introduction: The Role of σ1 Receptors in Some Brain Diseases

The σ1 receptor is highly expressed in the central nervous system (CNS) and therefore is centrally involved in various pathological conditions of the CNS. Therefore, the labeling of σ1 receptors with a positron emission tomography (PET) tracer, allowing non-invasive imaging, represents a valuable tool for target validation as well as diagnosis and prognosis. In this report, we will focus on the participation of the σ1 receptor in pain, psychosis, Alzheimer’s disease, and depression [1,2,3].

1.1. Pain

A functional connection between the σ1 and opioid receptor systems has been reported. The downregulation of the σ1 receptor led to an increased analgesic activity of opioid analgesics [2]. The same effect could be produced by σ1 receptor antagonists such as haloperidol (Figure 1). On the other hand, σ1 receptor agonists (e.g., (+)-pentazocine, Figure 1) resulted in reduced analgesia mediated by opioid (MOR) agonists [4]. However, σ1 receptors are also directly involved in pain sensation, in particular in the special type of neuropathic pain. While capsaicin produced mechanical allodynia in wild-type mice, it failed to induce the same effect in σ1 receptor knock-out mice. Furthermore, σ1 receptor antagonists could dose-dependently reduce capsaicin-mediated mechanical allodynia, while σ1 receptor agonists reversed this analgesic effect [5]. The σ1 receptor antagonist S1RA (Figure 1) represents the most advanced drug candidate, exhibiting high analgesic activity in animal models of neuropathic pain. S1RA is currently being investigated in a phase II clinical trial for the treatment of neuropathic pain [6,7].

1.2. Psychosis

Classical antipsychotics inhibit the G protein-coupled dopamine D2 receptor. However, the prototypical antipsychotic haloperidol (Figure 1) inhibits not only D2 receptors (binding affinity: Ki(D2) = 2.6 nM) [8], but also σ1 receptors with high affinity (Ki(σ1) = 6.2 nM) [9]. Other clinically used antipsychotics (e.g., chlorpromazine as a member of the class of phenothiazines, Figure 2) also show moderate to high σ1 receptor affinity [10]. It was hypothesized that the inhibition of σ1 receptors is capable of contributing to the overall antipsychotic effects of these D2 receptor antagonists [11]. In addition to these “mixed D2/σ1 receptor antagonists”, some ligands predominantly inhibiting σ1 receptors (e.g., eliprodil (SL82.0715), rimcazole (BW234U), panamesine (EMD57445), DuP734, and BMY14802 (BMS181100)) were tested in clinical trials for their potential use as antipsychotics. In Figure 2, the structures of eliprodil, rimcazole, and panamesine are shown, exemplarily [12].

1.3. Alzheimer’s Disease

The σ1 receptor agonist (+)-pentazocine was able to attenuate the memory deficits in mice treated with amyloid β25–35 (cerebroventricular application) in a dose-dependent mode. In animal models of Alzheimer’s disease (chronic intracerebroventricular infusion of the amyloid β1-40 protein), σ1 receptor agonists improved depressive behavior in mice [13,14]. The acetylcholinesterase inhibitor donepezil (Figure 3) is one of the first-line drugs used for the treatment of Alzheimer’s disease. In addition to the inhibition of acetylcholinesterase, donepezil can also activate σ1 receptors. It was hypothesized that the activation of σ1 receptors by donepezil contributes to its neuroprotective and anti-amnesic effects [15]. In PET studies, a low σ1 receptor density was found for patients at an early stage of Alzheimer’s disease [16].

1.4. Depression

Various studies have shown that σ1 receptors are involved in the pathology of depression. A depressive-like behavior was observed in σ1 receptor knock-out mice [17]. In the forced swimming test, which is used to evaluate antidepressant drugs, some σ1 receptor agonists exhibited antidepressant activity [18,19]. Furthermore, several clinically used antidepressants, such as tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), show moderate to high σ1 receptor affinity. Figure 4 displays imipramine and opipramol as examples of the class of tricyclic antidepressants, and fluvoxamine, fluoxetine, and sertraline as examples of SSRIs. The repeated treatment of rats with the antidepressants imipramine and fluvoxamine, but also with the σ1 receptor agonist (+)-pentazocine, led to the downregulation of σ1 receptors in some regions of the brain, including the striatum, hippocampus, and cerebral cortex [20,21].

2. Fluorinated PET Tracers Derived from the Promising σ1 Ligand Cutamesine (SA 4503)

The introduction of fluorine-18 into an aromatic ring requires the careful selection of appropriate precursors and longer reaction sequences. The introduction of fluorine-18 into aliphatic side chains by SN2-substitution is straightforward. However, aryl fluorides are usually rather stable in vivo, while alkyl fluorides carry the risk of defluorination, which would result in bone labeling via the formation of [18F]CaF2. Several PET tracers bearing aromatic and aliphatic fluorine-18 have been reported in the literature [16,22,23].
The most prominent fluorinated σ1 receptor-targeting PET tracers are derived from the σ1 receptor agonist cutamesine (SA 4503, Figure 5) [24]. Cutamesine has anti-amnestic activity and can reduce amnesia caused by REM sleep deprivation [25,26]. Furthermore, this σ1 receptor agonist showed antidepressant activity in the forced swimming test of rodents [27].
The fluoroethyl derivative FE-SA 4503 showed only moderate to low selectivity for the σ1 receptor over the σ2 subtype. In a PET study with rhesus monkeys, [18F]FE-SA 4503 exhibited fast uptake in the brain and enrichment in regions with high expression of σ1 receptors. However, an equilibrium of ligand binding to the σ1 receptor was not reached within 90 min [28]. Despite its α-fluoro ether substructure, the fluoromethyl derivative FM-SA 4503 displayed an unexpectedly high chemical stability in vitro and in vivo. The replacement of [18F]FM-SA 4503 with haloperidol in a study with rhesus monkeys revealed a higher specific binding of [18F]FM-SA 4503 than of [11C]SA 4503. Although [18F]FM-SA 4503 has an unconventional structure, it represents a promising fluorinated PET tracer for the labeling of σ1 receptors in the brain [29].
The 18F-labeled PET-tracers [18F]FE-SA 4503 and [18F]FM-SA 4503 (Figure 5) were synthesized in two-step sequences. At first, the 18F-labeled reagents [18F]FCH2CH2OTs and [18F]CH2BrF were prepared by the nucleophilic substitution of TsOCH2CH2OTs and H2CBr2, respectively, with the K[18F]F/Kryptofix system. In the second step, the phenolate precursor was reacted with [18F]FCH2CH2OTs and [18F]H2CBrF to afford the 18F-labeled PET tracers [18F]FE SA4503 and [18F]FM SA4503, respectively [28,29].

3. Spirocyclic σ1 Receptor Ligands Designed for PET Studies: Structure Affinity Relationships

We are particularly interested in drugs with a large number of sp3-hybridzed C-atoms incorporated in rigid scaffolds, such as spirocyclic, bicyclic, or propellane systems leading to defined three-dimensional frameworks with an exact orientation of functional groups and substituents. Therefore, we started to exploit the pharmacological potential, in particular the σ1 receptor affinity and selectivity, of spirocyclic piperidines.
A homologous series of fluoroalkyl-substituted spirocyclic piperidines 1–4 bearing a benzyl moiety at the piperidine N-atom was prepared. The four homologs 1–4 showed very high σ1 receptor affinities (Ki = 0.59–1.4 nM) and low σ2 receptor affinity (Ki = 489–837 nM), resulting in a high σ1:σ2 selectivity [30,31,32,33,34]. The highest σ1 receptor affinity and σ1:σ2 selectivity were observed for the fluoroethyl derivative 2 (Table 1). Therefore, the benzyl moiety of 2 was replaced by several other substituents including substituted benzyl, cyclohexylmethyl, and alkyl moieties. With the exception of the very lipophilic n-butyl and n-octyl derivatives 8 and 9, the modified spirocyclic piperidines 5–7 and 10 displayed high σ1 receptor affinity, but reduced selectivity over the σ2 receptor. In particular, the cyclohexylmethyl derivative 6 binds with subnanomolar affinity at σ1 receptors (Ki = 0.71 nM), but also with moderate affinity at σ2 receptors (Ki = 57 nM), leading to a low σ1:σ2 selectivity [31]. The very high σ1 receptor affinity (Ki = 0.59 nM) and σ1:σ2 selectivity (1331-fold) and the promising physicochemical properties (see Chapter 5) prompted us to further develop the fluoroethyl derivative 2, which was termed fluspidine.

4. Synthesis of Racemic and Enantiomerically Pure Fluspidine (2, (S)-2 and (R)-2)

For the synthesis of racemic fluspidine (2), two synthetic routes were pursued, both of which started with 2-bromobenzaldehyde (11) (Scheme 1). After the conversion of aldehyde 11 into dimethyl acetal 12, bromine–lithium exchange with n-BuLi led to an aryllithium intermediate, which reacted with 1-benzylpiperidin-4-one to provide the cyclic hemiacetal 13 after hydrolysis with HCl. The Domino reaction of the hemiacetal 13 with the Wittig reagent Ph3P=CHCO2Et consisted in the opening of the hemiacetal to form an hydroxy aldehyde, the Wittig reaction of the aldehyde to give an α,β-unsaturated ester, and finally an intramolecular Michael addition of the tertiary alcohol to the α,β-unsaturated ester to end up with the spirocyclic ester 14. The LiAlH4 reduction of the ester 14 provided the primary alcohol 18 [35].
According to the second route, the Wittig reaction of aldehyde 11 was first performed, leading to the α,β-unsaturated acetal 15. Bromine-lithium exchange followed by reaction with 1-benzylpiperidin-4-one provided the spirocyclic 2-benzoxepine 16, which upon hydrolysis with HCl led to ring contraction, giving the (2-benzofuranyl)acetaldehyde 17. Aldehyde 17 was reduced with NaBH4 to give the primary alcohol 18 [31] (Scheme 1).
The fluorinating reagent DAST (diethylaminosulfur trifluoride, Et2NSF3) converted the intermediate primary alcohol 18 directly into the fluoroethyl derivative 2 [31]. To prepare the radiosynthesis, the primary alcohol 18 was transformed into the tosylate 19, which reacted with TBAF (tetrabutylammonium fluoride, Bu4N+F−) to produce fluspidine (2) [36] (Scheme 1).
In order to obtain pure fluspidine enantiomers (R)-2 and (S)-2, the chiral resolution of racemic tosylate 19 was conducted. The enantiomeric tosylates (R)-19 and (S)-19 were separated using the Daicel® Chiralpak IB column and the eluent isohexane:ethanol 100:2, and the absolute configuration of the enantiomers was determined by CD spectroscopy. Both enantiomers, (R)-19 and (S)-19, were converted into the fluspidine enantiomers (R)-2 (99.6%ee) and (S)-2 (96.4%ee) using TBAF (Bu4NF) as a fluoride source for the SN2 substitution [36] (Scheme 2).
However, the separation of enantiomers inevitably leads to 50% waste, since only one of the enantiomers will be of interest for application as a PET tracer in human studies. Therefore, we developed a novel synthesis method with the enantioselective reduction of a double bond as the key step. Thus, the alkyne 22 was prepared by a Sonogashira reaction of 1-bromo-2-iodobenzene (20) with the terminal alkyne 21 bearing an orthoester functional group [37]. Bromine–lithium exchange at 22 and subsequent reaction with 1-benzylpiperidin-4-one directly led to the α,β-unsaturated ester 23. The best method for the enantioselective reduction of the α,β-unsaturated ester 23 appeared to be the reduction with NaBH4 in the presence of chiral co-catalysts (R,R)-24 and (S,S)-24 [38]. The enantiomeric excess was determined after the additional reduction of the ester moiety to a primary alcohol. The reduction of the α,β-unsaturated ester 23 with NaBH4 in the presence of (R,R)-24 (0.01 equivalents) led to the alcohol (R)-18 in a 63% yield and 95.6%ee. The enantiomeric co-complex (S,S)-24 (0.01 equivalents) resulted in an 82% yield of (S)-18 and 97.2%ee [39]. Transformation of the primary alcohols (R)-18 and (S)-18 did not change the enantiomeric excess considerably. As the stereocontrol of the co-catalysts (R,R)-24 and (S,S)-24 has been thoroughly investigated, the application in the enantioselective synthesis of both fluspidine enantiomers confirmed the assignment of their absolute configuration by CD-spectroscopy (Scheme 3).
In an alternative enantioselective synthesis of both fluspidine enantiomers (R)-2 and (S)-2, (Z)-configured methyl 3-silyloxy-3-(2-bromophenyl)acrylate was enantioselectively reduced with the same co-catalysts (R,R)-24, (S,S)-24 and NaBH4. However, the establishment of the spirocyclic framework of fluspidine required six additional reaction steps, starting with a Suzuki coupling [40].
Both enantiomers showed very high σ1 receptor affinity with Ki values of 0.57 nM for (R)-2 and 2.3 nM for (S)-2. Moreover, NMDA receptors with a GluN2B subunit and opioid receptors have been determined to have high selectivity over the σ2 subtype.

5. In Vitro Characterization of Fluspidine and Its Enantiomers

The lipophilicity of the homologous fluoroalkyl derivatives 1–4 was determined by the micro-shake flask method. After the distribution of the compounds between an n-octanol layer and MOPS buffer (pH 7.4), the amount of the compound in the buffer layer was determined by mass spectrometry [41,42]. The recorded logD7.4 values were compared with the logD7.2 values determined by the distribution of the analogous 18F-labeled compounds [18F]1–[18F]4 between n-octanol and phosphate-buffered saline, pH 7.2. The logD7.2 values were calculated from the distribution of radioactivity in both layers.
In Table 2, the determined logD7.4 and logD7.2 values are summarized. As expected, the logD7.4 and logD7.2 values increased with the increasing length of the fluoroalkyl side chain from 2.80 (1) to 3.71 (4) and 2.39 (1) t0 3.11 (4), respectively. The logD7.4 and logD7.2 values of all four homologs we in a promising range. It should be emphasized that the logD7.4 and logD7.2 values determined by different methods showed a very good correlation [30,32,33,34].
Plasma protein binding was recorded by HPLC analysis using a stationary phase coated with human serum albumin. The resulting retention times correlate with binding to human serum albumin [42]. The least lipophilic fluoromethyl derivative 1 exhibited the lowest plasma protein binding (84%), which increased with the increasing length of the fluoroalkyl side chain up to 95% for the fluorobutyl derivative 4 (Table 2).
Metabolic stability was initially determined by microsomal assays involving incubation of the homologous fluoroalkyl derivatives 1–4 with mouse liver microsomes and NADPH. After an incubation period of 90 min, the amount of remaining test compound was determined by LC-MS [42,43,44]. Under standardized conditions, the metabolic stability decreased with increasing lipophilicity. While the fluoromethyl derivative 1 revealed moderate stability (53% intact after 90 min), the longer homologs 2, 3 and 4 showed reduced metabolic stability, with only 34%, 33% and 28% of intact parent compounds 2, 3 and 4 after 90 min, respectively (Table 2).
The metabolites formed upon incubation of 2, (R)-2, and (S)-2 with rat liver microsomes and NADPH were analyzed by LC-MS and MSn experiments. Figure 6 shows the formed metabolites. The N-debenzylated metabolite 2a and the p-hydroxyphenyl metabolite 2c represent the main metabolites. The structures of both metabolites were confirmed by independent synthesis. Two metabolites bearing OH moieties in the piperidine ring (2b) and the fluoroethyl side chain (2h) as well as the N-oxide 2d could be detected. Furthermore, three metabolites 2e–2g containing two additional O-atoms were detected. Interestingly, the metabolite 2h with the additional OH moiety in the fluoroethyl side chain was formed only for the (S)-configured enantiomer [36].

6. Molecular Interactions of Fluspidine Enantiomers with the σ1 Receptor

Molecular dynamics (MD) simulations were employed to elucidate the interactions between the two fluspidine enantiomers (R)-2 and (S)-2 and the σ1 receptor. The X-ray crystal structure 5HK1 [45] of the σ1 receptor from the PDB repository was used for the computational studies. The computational investigation primarily focused on evaluating their binding affinity, examining the patterns of interaction, and assessing potential selectivity based on the orientation of key functional groups. For this purpose, both enantiomers (R)-2 and (S)-2 were modeled and docked into the binding site of the σ1 receptor, and the relevant free energy of binding (ΔGbind) between the protein and the enantiomers was determined using MM/PBSA calculations [46]. As shown in Figure 7A,B, the analysis of the MD trajectories reveals that both (R)-fluspidine and (S)-fluspidine bind the σ1 receptor via the four canonical forms of interactions [9,23,47,48]: (i) a stable salt bridge is established between the positively charged R3NH+ group of the piperidine ring of the ligand and the negatively charged COO- group of E172. This interaction is facilitated by an optimal arrangement that involves an additional hydrogen bond with Y103. (ii) The aromatic side chain of F107 contributes to the stabilization of the intermolecular complex through a strong π-cation interaction with the aforementioned protonated N-atom of the ligands. (iii) The analysis also highlights the presence of a robust network of hydrophobic and π–π interactions between the benzyl moiety of the fluspidine enantiomers and the aromatic groups of σ1 receptor residues W89, Y120, and W164. These interactions effectively secure the ligand within the protein binding cavity. (iv) Furthermore, several additional hydrophobic interactions contribute to the stability of the ligand/receptor complex. These interactions mainly involve the 2-benzofuran ring and the side chains of the σ1 receptor residues lining the hydrophobic pocket, namely, M93, L105, T181, L182, and T202.
In summary, modeling investigations suggest that both enantiomers (R)-2 and (S)-2 of fluspidine fit well in the binding site of the σ1 receptor by establishing similar stabilizing interactions with the receptor. To quantify these interactions, binding free energy calculations were performed. According to these simulations, the affinities of both enantiomers for the σ1 receptor are comparable. In fact, the receptor exhibits a marginally higher affinity for the (R)-configured enantiomer over the (S)-enantiomer, as indicated by the corresponding ΔGbind values of −11.21 ± 0.19 kcal/mol and −10.96 ± 0.21 kcal/mol, respectively.
To gain further insight into the receptor binding of the two fluspidine enantiomers, the enthalpic component (ΔHbind) of the binding free energy was decomposed into the contributions provided by the protein residues primarily engaged in each ligand binding. (Figure 8A). The results of this analysis indicate that the significant interaction involving E172 has comparable effects on the stabilization of (R)-2 (ΣΔHres = −4.99 kcal/mol) and (S)-2 (ΣΔHres = −5.03 kcal/mol). Additionally, the π-cation interaction with F107 contributes to the stabilization of the (R)-2 and (S)-2 with comparable ΣΔHres values (−2.71 kcal/mol and −2.77 kcal/mol, respectively). Furthermore, the estimated hydrophobic and π-π interactions involving the side chains of residues W89, Y120, and W164 are also almost identical (ΣΔHres = −4.18 kcal/mol for (R)-2 and ΣΔHres = −4.15 kcal/mol for (S)-2, respectively), supporting the idea that all the interactions described above almost equally contribute to stabilizing (R)-2 and (S)-2 in the binding pocket.
On the other hand, the marginal disparity in binding affinity of the σ1 receptor for the two fluspidine enantiomers (R)-2 and (S)-2 can be rationalized by analyzing the stabilizing interactions performed by the ligands in the remaining part of the receptor, that is, the hydrophobic pocket involving residues M93, L105, T181, L182, and T202 (Figure 8B,C), for which the calculated ΣΔHres values are −5.21 kcal/mol and −4.88 kcal/mol for (R)-2 and (S)-2, respectively.
Beyond these typical hydrophobic interactions, the analysis also revealed that (R)-2 exhibits an additional weak electrostatic contact between the fluoroethyl moiety and the hydroxy group of T202. Accordingly, in the case of (R)-2, the average dynamic distance (ADD) between these two groups of atoms, as recorded throughout the molecular simulations, is considerably shorter (ADD = 3.98 ± 0.12 Å) compared to that observed for (S)-2 (ADD = 5.15 ± 0.19 Å). In conclusion, the structural and energetic evidence provided in this study provides a molecular-based rationale for the slightly higher binding affinity of the σ1 receptor for the (R)-configured enantiomer (R)-2 of fluspidine.

7. Radiosynthesis

In nuclear medicine, fluorine-18-labeled PET tracers have emerged as powerful tools for non-invasive molecular imaging. The physical and nuclear properties of fluorine-18 (t½ = 109.8 min, 97% e+ (β+) decay, e+ energy 635 keV) [49] and its availability in cyclotron facilities render fluorine-18 superior to other radionuclides. The broad applicability of fluorine-18 was driven by the development of novel radiofluorination methods [50] and the automate-supported production of PET tracers.
The PET tracers [18F]2–[18F]4 were prepared by the nucleophilic substitution of the corresponding tosylate precursors with [18F]fluoride. For this purpose, the cryptand K2.2.2 and K2CO3 were added to the aqueous [18F]fluoride solution delivered from the cyclotron, followed by the removal of water by azeotropic drying to obtain “naked” and highly nucleophilic [18F]fluoride for the radiolabeling step. The PET tracers [18F]2–[18F]4 were obtained with 35–51% radiochemical yields, high radiochemical purity and high molar activity [32,33,34] (Table 3). However, the synthesis of the fluoromethyl derivative [18F]1 from the corresponding tosylate required the solvent DMSO at 150 °C instead of CH3CN at 85 °C. The solvent DMSO and the higher reaction temperature were necessary due to the branched system (2-benzofuran) in the β-position of the tosyloxy moiety. The branch close to the reaction center inhibited the backside attack of the nucleophile [18F]fluoride. Under these reaction conditions, the radiochemical yield, radiochemical purity, and molar activity of [18F]1 were comparable to those of [18F]2–[18F]4, while the reaction time was even shorter [30] (Table 3). After the synthesis, PET tracers [18F]1–[18F]4 were formulated in saline for further investigation and for the first preclinical studies. The total synthesis time was 80–100 min for [18F]1 and 90–120 min for [18F]2–[18F]4.
Since the PET tracers [18F]2, (R)-[18F]2 and (S)-[18F]2 were set for clinical use, automated syntheses were developed using a TRACERlab FX FN synthesis module. The tosylate precursors 19, (R)-19 and (S)-19 were reacted with [18F]fluoride to obtain the PET tracers [18F]2, (R)-[18F]2 and (S)-[18F]2 by nucleophilic substitution. After some optimization and adaptation experiments, the PET tracers [18F]2, (R)-[18F]2 and (S)-[18F]2 were obtained with high radiochemical yields, high radiochemical purity, high molar activity and short reaction times [51,52] (Scheme 4, Table 4).

8. Preclinical In Vivo Studies of Racemic and Enantiomerically Pure [18F]Fluspidine [18F]2, (R)-[18F]2 and (S)-[18F]2

8.1. Radiometabolites of rac-[18F]2, (R)-[18F]2 and (S)-[18F]2 In Vivo

Before detailed preclinical studies were performed using different species, the presence of radiometabolites in the brain was investigated. In the brains of CD-1 mice, 98% of the activity was due to rac-[18F]2 60 min after intravenous administration of the radioligand, indicating the almost complete absence of brain-penetrant radiometabolites [53]. At the same time, the proportion of unchanged PET tracer rac-[18F]2 in mouse plasma was still 75%. In piglets, the metabolisms of the two enantiomers (R)-[18F]2 and (S)-[18F]2 were compared, and plasma samples revealed a higher stability of the (S)-configured enantiomer [52], although this was lower than in mice (Figure 9). On the contrary, (R)-[18F]2 and (S)-[18F]2 showed comparable fractions of unchanged PET tracer in plasma in rhesus monkeys (>30%, 60 min p.i.) [54], which were in the same range as for (S)-[18F]2 in piglets.

8.2. Organ Distribution in Mice, Piglets and Non-Human Primates

The pharmacokinetic properties of rac-[18F]2 were first investigated by ex vivo organ distribution studies carried out in female CD1-mice [32]. Tissues and organs of interest were isolated at different times after the intravenous (i.v.) administration of the radiotracer to measure the radioactivity. Organ activity time data show a rapid, high and slowly increasing uptake of rac-[18F]2 in the brain (3.88 and 4.71% of injected dose per g (% ID/g) at 5 and 30 min p.i., respectively), with an activity distribution similar to the immunohistochemical distribution of the σ1 receptor in the mouse brain [55]. The rapid uptake in the brain was followed by a slow washout (2.82% ID/g at 120 min p.i.). The significant reduction in activity uptake after blocking the σ1 receptor by the previous application of haloperidol confirmed the target specificity of rac-[18F]2 in vivo (Table 5).
To evaluate the potential use of the 18F-labelled enantiomers (R)-[18F]2 and (S)-[18F]2 for neuroimaging in a large animal model and to establish a modeling method for the accurate quantification of the σ1 receptors in the brain, PET studies were conducted in piglets [52]. These studies showed that both radiotracers (R)-[18F]2 and (S)-[18F]2 are rapidly taken up throughout the brain with a standardized uptake value (SUV) of about 2 within 3 min after injection. The specific binding of both radiotracers to the σ1 receptor in the piglet brain was confirmed by the faster brain washout and the reduced activity observed after the blocking of σ1 receptors with SA 4503. Furthermore, the metabolic and brain time–activity curve profiles of both radiotracers indicate the absence of radiometabolites penetrating the blood–brain barrier in the piglets.
However, the differences in the brain uptake kinetics of the two enantiomers in baseline studies indicate that their suitability for diagnostic imaging varies in several pathological situations. Although both enantiomers exhibited similar initial brain uptake, the clearance of (R)-[18F]2 was noticeably slower than that of (S)-[18F]2 (SUV120min p.i.: ~80% vs. ~50% of SUV5min p.i.). Due to the absence of a reference region with no or very low specific uptake in the pig brain, compartmental modeling and graphical analyses were utilized to analyze the dynamic imaging data to obtain measures for the specific binding of both radiotracers. A full, nonlinear kinetic analysis of the baseline scans using metabolite-corrected plasma input function and two-tissue compartment modeling has revealed whole-brain distribution volumes of VT = 13 and 133 mL/g for (S)-[18F]2 and (R)-[18F]2, respectively. Furthermore, data obtained from the Logan plot analysis [56] demonstrate a decrease in VT values upon SA 4503′s blockade of the σ1 receptors (whole brain (S)-[18F]2: −55%, (R)-[18F]2: −89%), confirming the specific binding of both radiotracers.
While the results of the preclinical studies suggest that (S)-[18F]2 is appropriate for the quantitative neuroimaging of the σ1 receptor and for occupancy evaluations of σ1 receptor-targeting drugs [57], the time–activity curves of (R)-[18F]2 indicate an apparently irreversible binding to the σ1 receptor. This hypothesis was supported by mouse dosimetry studies [58], PET imaging evaluation in non-human primates [54], and in vitro association and dissociation studies [54], demonstrating the extremely slow washout of (R)-[18F]2 from the brain in vivo and the negligible dissociation of (R)-[18F]2 from the binding site in vitro. However, the distribution pattern of (R)-[18F]2 and the much more rapidly cleared (S)-[18F]2 in the brain of rhesus monkeys (Table 5) reflect those of other σ1 receptor-specific radiotracers in this species. Finally, the rapid brain uptake kinetics, favorable metabolic profile, and high specific signal observed in studies carried out in non-human primates by Baum et al. [54] confirmed the efficacy of (S)-[18F]2 in quantifying brain σ1 receptor expression levels.
In a mouse model of glioblastoma multiforma, an increased σ1 receptor density in the tumor was detected with (S)-[18F]2. An increased σ1 receptor density was also observed during an autoradiographic analysis of samples from patients with glioblastoma using (S)-[18F]2, confirming the translational relevance of σ1 receptor imaging in oncology [59].

9. Human Studies with (S)-[18F]Fluspidine ((S)-[18F]2)

Imaging of σ1 Receptors in a Clinical Study (Major Depressive Disorder Patients)

Following preclinical evaluation, the team of Osama Sabri at the Department of Nuclear Medicine of the University of Leipzig, Germany, completed a first-in-man incorporation dosimetry study that initiated successful human PET trials with (S)-[18F]2 [60]. The objective of this first clinical proof-of-concept study (DRKS00008321) was to test (S)-[18F]2 in patients with major depressive disorder (MDD) compared to healthy subjects, in accordance with evidence for the antidepressant-like effects of agonistic σ1 receptor ligands [61].
By kinetic modeling using a 1TCM or 2TCM model, the total volume of distribution (VT) of (S)-[18F]2 can be estimated for all cortical regions from PET 90 min time–activity curves (TACs) with robust and feasible results [62]. Consequently, a PET study with (S)-[18F]2 is a suitable method for quantifying σ1 receptor availability and related changes in neuropsychiatric diseases due to its high VT and short measurement times. In a study on depression conducted in rats, it was found that MDD rats had decreased levels of cardiac σ1 receptors [63]. Additionally, the genetic inhibition of the σ1 receptor in σ1 knock-out mice led to a depressive-like phenotype [17].
Interestingly, in unmedicated patients with acute early-onset MDD, a PET study with (S)-[18F]2 revealed an increased availability of σ1 receptors in cortico-striato-(para)limbic brain regions compared to healthy volunteers. This increase was strongly correlated with the severity of acute depressive symptoms of MDD and is believed to reflect neuro-adaptive upregulation, which counteracts endoplasmic reticulum (ER) stress [62]. Unfortunately, although the authors of this study suggested additional PET studies with (S)-[18F]2 to investigate σ1 receptor availability in a larger group of patients with depression in different stages of disease and during treatment, it appears that this study has not been planned or performed, leaving a gap in our understanding of the pathophysiology of the σ1 receptor in the context of MDD.
However, during the study mentioned above, the metabolism of (S)-[18F]2 was investigated and a high fraction of unchanged PET tracer (S)-[18F]2 was found in human plasma (see Figure 10) [62,64].
In contrast, a high fraction of a single radiometabolite, [18F]2i, and only very small amounts of the unchanged PET tracer (S)-[18F]2 were detected in urine. With the aid of in vitro experiments and LC-MS studies, the structures of the main metabolites were elucidated. The glucuronide [18F]2i represents the main metabolite, which originated from the glucuronidation of the hydroxy metabolite [18F]2h. The secondary amine [18F]2a produced by N-debenzylation was detected as a minor metabolite of the PET tracer (S)-[18F]2 (Figure 11).
In addition to non-invasively assessing the expression levels of σ1 receptors subjected to pathological modifications, supporting the evaluation of σ1 receptor as a biomarker for diseases of the CNS, neuroimaging by PET with (S)-[18F]2 allows occupancy studies supporting the development of novel therapeutic drugs. The objective of a corresponding study (NCT03019289), undertaken by Osama Sabri’s team, was to demonstrate the target specificity of pridopidine, a drug originally designed for the treatment of CNS pathologies associated with dysfunction of the dopaminergic neurotransmission. Pridopidine (4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine), also known as ACR-16, ASP 2314, FR 310,826 or Huntexil, was originally developed by Arvid Carlsson Research AB as a dopamine stabilizer to reduce hyperactivity and increase behavioral complexity in hypoglutamatergic mice, a model of cognitive deficits in schizophrenia (Figure 12) [65].
The pharmacological properties of this compound made it an interesting candidate for the treatment of a wide range of neurological and psychiatric disorders, such as L-DOPA-induced dyskinesia associated with levodopa treatment in Parkinson’s disease [66,67,68]. Due to neuroprotective effects observed in models of Huntington’s disease (HD) [69], pridopidine was further developed for the treatment of motor symptoms associated with HD. However, different phase 3 studies, initiated by various companies developing pridopidine for clinical applications in HD patients, led to negative results. Therefore, the mechanism of action of pridopidine was reexamined, and a receptor occupancy study in rats indicated the preferential binding of pridopidine to the σ1 receptor compared to dopamine D2 receptors [69]. In addition, a study in genetically modified mice identified the σ1 receptor as a mediator of pridopidine-induced gene expression in the brain, contributing to the neuromodulatory effects of this drug [70]. These findings suggest that the interaction of pridopidine with the σ1 receptor in humans should be investigated in more detail.
In (S)-[18F]2, a tool is available that allows the non-invasive evaluation of the occupancy of the σ1 receptor by drugs in the human body using PET [71]. The free fraction in blood plasma of (S)-[18F]2 available for brain uptake has been determined as fp = 0.023. VT measurements in healthy volunteers confirmed the results of the preclinical studies performed with (S)-[18F]2 in pigs and NHPs discussed above, with values of, e.g., 21 mL/g in the frontal cortex and 19 mL/g in the striatum. The results of the occupancy study using (S)-[18F]2 in a PET study indicated the selective binding of pridopidine to the σ1 receptor in the brains of healthy volunteers and HD patients at therapeutic doses. On the contrary, only minimal occupancy of dopamine D2/D3 receptors was found [71].

10. Computational Details

The crystal structures of the σ1 receptor were obtained from the available PDB file in the Protein Data Bank repository, 5HK1 [45]. All docking experiments were carried out with Autodock 4.2.6/Autodock Tools1.4 [72] on a win64 platform, following a consolidated procedure [9,47,48]. The resulting docked complexes were solvated with explicit TIP3P [73] water, and then the density and the volume of the system were relaxed in the NPT ensemble, maintaining the Berendsen barostat for 20 ns. After this step, 100 ns of unrestrained NVT production simulation was run for each system. According to this computational recipe, ΔGbind values are calculated for equilibrated structures extracted from the corresponding molecular dynamics (MD) by following the MM/PBSA approach [45]. The per residue binding free-energy decomposition was performed using the same MD trajectory of each ligand/σ1 complex, with the objective of identifying the key residues involved in the ligand/receptor interaction. This analysis was carried out using the MM/GBSA approach [74], and was based on the same snapshots used in the calculation of the binding free-energy. All simulations were carried out using Amber 21 [75] running on the Marconi100 GPU/CPU supercomputer (CINECA, Bologna, Italy). MarvinSketch was used to draw and display the input chemical structures (Version 23.12.0), ChemAxon Software (http://www.chemaxon.com). All images were created in the UCSF Chimera software (version 1.17.3) [76] and the graphs were produced in GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA, www.graphpad.com).

11. Determination of In Vitro Pharmacokinetic Parameters

The pharmacokinetic parameters logD7.4 value, plasma protein binding and metabolic stability described in Table 2 were determined according to references [41,42].

Author Contributions

Conceptualization, B.W.; data in Table 2 were recorded by J.S.; molecular interactions were analyzed and described by E.L. and S.P.; Section 7, Section 8 and Section 9 were prepared by F.-A.L. and W.D.-C.; writing—review and editing, B.W., F.-A.L., W.D.-C., E.L. and S.P. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Deutsche Forschungsgemeinschaft (DFG), which is gratefully acknowledged. SP and EL acknowledge access to supercomputing resources and financial support from ICSC—Centro Nazionale di Ricerca in high-performance computing, big data, and quantum computing (Spoke 7), WP4 (Pilot applications), T.2.8 (Development and optimization of HPC-based integrated workflows based on flagship codes for personalized (nano)medicine) and CINECA, funded by European Union—NextGenerationEU.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Cobos, E.J.; Entrena, J.M.; Nieto, F.R.; Cendan, C.M.; Del Pozo, E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr. Neuropharmacol. 2008, 6, 344–366. [Google Scholar] [CrossRef]
  2. Maurice, T.; Su, T.-P. The Pharmacology of Sigma-1 Receptors. Pharmacol. Ther. 2009, 124, 195–206. [Google Scholar] [CrossRef]
  3. Smith, S. Sigma Receptors: Their Role in Disease and as Therapeutic Targets; Springer: Berlin/Heidelberg, Germany; New York, NY, USA, 2016. [Google Scholar]
  4. Chien, C.C.; Pasternak, G.W. Selective antagonism of opioid analgesia by a sigma system. J. Pharmacol. Exp. Ther. 1994, 271, 1583–1590. [Google Scholar]
  5. Entrena, J.M.; Cobos, E.J.; Nieto, F.R.; Cendan, C.M.; Gris, G.; Del Pozo, E.; Zamanillo, D.; Baeyens, J.M. σ1 receptors are essential for capsaicin-induced mechanical hypersensitivity: Studies with selective σ1 ligands and σ1 knockout mice. Pain 2009, 143, 252–261. [Google Scholar] [CrossRef]
  6. Diaz, J.L.; Cuberes, R.; Berrocal, J.; Contijoch, M.; Christmann, U.; Fernandez, A.; Port, A.; Holenz, J.; Buschmann, H.; Laggner, C.; et al. Synthesis and biological evaluation of the 1-arylpyrazole class of σ1 receptor antagonists: Identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862). J. Med. Chem. 2012, 55, 8211–8224. [Google Scholar] [CrossRef]
  7. Wünsch, B. The σ1 receptor antagonist S1RA is a promising candidate for the treatment of neurogenic pain. J. Med. Chem. 2012, 55, 8209–8210. [Google Scholar] [CrossRef]
  8. Richelson, E.; Souder, T. Binding of antipsychotic drugs to human brain receptors Focus on newer generation compounds. Life Sci. 2000, 68, 29–39. [Google Scholar] [CrossRef]
  9. Blicker, L.; Gonzáles-Cano, R.; Laurini, E.; Nieto, F.R.; Schmidt, J.; Schepmann, D.; Pricl, S.; Wünsch, B. Conformationally restricted σ1 receptor antagonists from (−)-isopulegol. J. Med. Chem. 2023, 66, 4999–5020. [Google Scholar] [CrossRef]
  10. Milenina, L.S.; Krutetskaya, Z.I.K.; Antonov, V.G.; Krutetskaya, N.I. Sigma-1 receptor ligands chlorpromazine and trifluoperazine attenuate Ca2+ responses in rat peritoneal macrophage. Cell Tissue Biol. 2022, 16, 233–244. [Google Scholar] [CrossRef]
  11. Ohi, K.; Hashimoto, R.; Yasuda, Y.; Fukumoto, M.; Yamamori, H.; Umeda-Yano, S.; Kamino, K.; Ikezawa, K.; Azechi, M.; Iwase, M.; et al. The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex. Prog. Neuro-Psychopharmacol. Biol. Psych. 2011, 35, 1309–1315. [Google Scholar] [CrossRef]
  12. Hayashi, T.; Tsai, S.Y.; Mori, T.; Fujimoto, M.; Su, T.P. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin. Ther. Targets 2011, 15, 557–577. [Google Scholar] [CrossRef]
  13. Urani, A.; Romieu, P.; Roman, F.J.; Maurice, T. Enhanced antidepressant effect of sigma1 (σ1) receptor agonists in σ25–35-amyloid peptide-treated mice. Behav. Brain Res. 2002, 134, 239–247. [Google Scholar] [CrossRef]
  14. Urani, A.; Romieu, P.; Roman, F.J.; Yamada, K.; Noda, Y.; Kamei, H.; Manh Tran, H.; Nagai, T.; Nabeshima, T.; Maurice, T. Enhanced antidepressant efficacy of σ1 receptor agonists in rats after chronic intracerebroventricular infusion of σ-amyloid-(1–40) protein. Eur. J. Pharmacol. 2004, 486, 151–161. [Google Scholar] [CrossRef]
  15. Meunier, J.; Ieni, J.; Maurice, T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25–35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br. J. Pharmacol. 2006, 149, 998–1012. [Google Scholar] [CrossRef]
  16. Wang, T.; Jia, H. The sigma receptors in Alzheimer’s Disease: New potential targets for diagnosis and therapy. Int. J. Mol. Sci. 2023, 24, 12025. [Google Scholar] [CrossRef]
  17. Sabino, V.; Cottone, P.; Parylak, S.L.; Steardo, L.; Zorrilla, E.P. σ1 receptor knockout mice display a depressive-like phenotype. Behav. Brain Res. 2009, 198, 472–476. [Google Scholar] [CrossRef]
  18. Hayashi, T.; Su, T.P. An update on the development of drugs for neuropsychiatric disorders: Focusing on the σ1 receptor ligand. Expert. Opin. Ther. Targets 2008, 12, 45–58. [Google Scholar] [CrossRef]
  19. Lucas, G.; Rymar, V.V.; Sadikot, A.F.; Debonnel, G. Further evidence for an antidepressant potential of the selective σ1 agonist SA 4503: Electrophysiological, morphological and behavioural studies. Int. J. Neuropsychopharmacol. 2008, 11, 485–495. [Google Scholar] [CrossRef]
  20. Shirayama, Y.; Nishikawa, T.; Umino, A.; Takahashi, K. p-chlorophenylalanine-reversible reduction of σ binding sites by chronic imipramine treatment in rat brain. Eur. J. Pharmacol. 1993, 237, 117–126. [Google Scholar] [CrossRef]
  21. Shirayama, Y.; Nishikawa, T.; Takahashi, K. Differential effects of repeated dl-pentazocine treatment on σ binding sites in discrete brain areas of the rat. Neurosci. Lett. 1994, 165, 219–222. [Google Scholar] [CrossRef]
  22. Brust, P.; Deuther-Conrad, W.; Lehmkuhl, K.; Jia, H.; Wünsch, B. Molecular Imaging of σ1 Receptors In Vivo: Current Status and Perspectives. Curr. Med. Chem. 2014, 21, 35–69. [Google Scholar] [CrossRef]
  23. Weber, F.; Brust, P.; Laurini, E.; Pricl, S.; Wünsch, B. Fluorinated PET tracers for molecular imaging of σ1 receptors in the central nervous system. In Sigma Receptors: Their Role in Disease and as Therapeutic Targets; Advances in Experimental Medicine and Biology; Springer International Publishing: Berlin/Heidelberg, Germany, 2017; Volume 964, pp. 31–48. [Google Scholar]
  24. Xu, R.; Lord, S.A.; Peterson, R.M.; Fergason-Cantrell, E.A.; Lever, J.R.; Lever, S.Z. Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): Effects on binding affinity and selectivity for sigma receptors and monoamine transporters. Bioorg. Med. Chem. 2015, 23, 222–230. [Google Scholar] [CrossRef]
  25. Matsuno, K.; Senda, T.; Kobayashi, T.; Okamoto, K.; Nakata, K.; Mita, S. SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties. Behav. Brain Res. 1997, 83, 221–224. [Google Scholar] [CrossRef]
  26. Ramakrishnan, N.K.; Schepers, M.; Luurtsema, G.; Nyakas, C.J.; Elsinga, P.H.; Ishiwata, K.; Dierckx, R.A.J.O.; van Waarde, A. Cutamesine Overcomes REM Sleep Deprivation-Induced Memory Loss: Relationship to Sigma-1 Receptor Occupancy. Mol. Imaging Biol. 2015, 17, 364–372. [Google Scholar] [CrossRef]
  27. Skuza, G. Potential antidepressant activity of sigma ligands. Pol. J. Pharmacol. 2003, 55, 923–934. [Google Scholar]
  28. Elsinga, P.H.; Kawamura, K.; Kobayashi, T.; Tsukada, H.; Senda, M.; Vaalburg, W.; Ishiwata, K. Synthesis and evaluation of [18F]fluoroethyl SA4503 as a PET ligand for the σ receptor. Synapse 2002, 43, 259–267. [Google Scholar] [CrossRef]
  29. Kawamura, K.; Tsukada, H.; Shiba, K.; Tsuji, C.; Harada, N.; Kimura, Y.; Ishiwata, K. Synthesis and evaluation of fluorine-18-labeled SA4503 as a selective σ1 receptor ligand for positron emission tomography. Nucl. Med. Biol. 2007, 34, 571–577. [Google Scholar] [CrossRef]
  30. Maisonal, A.; Maestrup, E.G.; Wiese, C.; Hiller, A.; Schepmann, D.; Fischer, S.; Deuther-Conrad, W.; Steinbach, J.; Brust, P.; Wünsch, B. Synthesis, radiofluorination and pharmacological evaluation of a fluoromethyl spirocyclic PET tracer for central σ1 receptors and comparison with fluoroalkyl homologs. Bioorg. Med. Chem. 2012, 20, 257–269. [Google Scholar] [CrossRef]
  31. Maestrup, E.G.; Wiese, C.; Schepmann, D.; Brust, P.; Wünsch, B. Synthesis, pharmacological activity and structure affinity relationships of spirocyclic σ1 receptor ligands with a (2-fluoroethyl) residue in 3-position. Bioorg. Med. Chem. 2011, 19, 393–405. [Google Scholar] [CrossRef]
  32. Fischer, S.; Wiese, C.; Maestrup, E.G.; Hiller, A.; Deuther-Conrad, W.; Scheunemann, W.; Schepmann, D.; Steinbach, J.; Wünsch, B.; Brust, P. Molecular imaging of σ receptors: Synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 540–551. [Google Scholar] [CrossRef]
  33. Große Maestrup, E.; Fischer, S.; Wiese, C.; Schepmann, D.; Hiller, A.; Deuther-Conrad, W.; Steinbach, J.; Wünsch, B.; Brust, P. Evaluation of spirocyclic 3-(3-fluoropropyl)-2-benzofurans as σ1 receptor ligands for neuroimaging with positron emission tomography. J. Med. Chem. 2009, 52, 6062–6072. [Google Scholar] [CrossRef]
  34. Maisonial, A.; Maestrup, E.G.; Fischer, S.; Hiller, A.; Scheunemann, M.; Wiese, C.; Schepmann, D.; Steinbach, J.; Deuther-Conrad, W.; Wünsch, B.; et al. A 18F-labeled fluorobutyl-substituted spirocyclic piperidine derivative as a selective radioligand for PET imaging of sigma1 receptors. ChemMedChem 2011, 6, 1401–1410. [Google Scholar] [CrossRef]
  35. Maier, C.A.; Wünsch, B. Novel σ receptor ligands. part 2. SAR of spiro[[2]benzopyran-1,4′-piperidines] and spiro[[2]benzofuran-1,4′-piperidines] with carbon substituents in position 3. J. Med. Chem. 2002, 45, 4923–4930. [Google Scholar] [CrossRef]
  36. Holl, K.; Falck, E.; Köhler, J.; Schepmann, D.; Humpf, H.-U.; Brust, P.; Wünsch, B. Synthesis, characterization, and metabolism studies of fluspidine enantiomers. Chem. Med. Chem. 2013, 12, 2047–2056. [Google Scholar] [CrossRef]
  37. Bunse, P.; Würthwein, E.-U.; Wünsch, B. Synthesis of substituted 1-alkylidenephthalanes via lithium-promoted 5-exo-dig cyclization. Eur. J. Org. Chem. 2018, 1806–1812. [Google Scholar] [CrossRef]
  38. Shuto, Y.; Yamamura, T.; Tanaka, S.; Yoshimura, M.; Kitamura, M. Asymmetric NaBH41,4-Reduction of C3-Disubstituted 2-Propenoates Catalyzed by a Diamidine Cobalt Complex. ChemCatChem 2015, 7, 1547–1550. [Google Scholar] [CrossRef]
  39. Bunse, P.; Schlepphorst, C.; Glorius, F.; Kitamura, M.; Wünsch, B. Short and atom-economic enantioselective synthesis of the σ1 receptor ligands (S)- and (R)-fluspidine—Important tools for positron emission tomography studies. J. Org. Chem. 2019, 84, 13744–13754. [Google Scholar] [CrossRef]
  40. Nakane, S.; Yoshinaka, S.; Iwase, S.; Shuto, Y.; Bunse, P.; Wünsch, B.; Tanaka, S.; Kitamura, M. Synthesis of fluspidine via asymmetric NaBH4 reduction of silicon enolates of β-keto esters. Tetrahedron 2018, 74, 5069–5084. [Google Scholar] [CrossRef]
  41. Galla, F.; Bourgeois, C.; Lehmkuhl, K.; Schepmann, D.; Soeberdt, M.; Lotts, T.; Abels, C.; Ständer, S.; Wünsch, B. Effects of polar κ receptor agonists designed for the periphery on ATP-induced Ca2+ release from keratinocytes. Med. Chem. Commun. 2016, 7, 317–326. [Google Scholar] [CrossRef]
  42. Börgel, F.; Galla, F.; Lehmkuhl, K.; Schepmann, D.; Ametamey, S.M.; Wünsch, B. Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold. J. Pharm. Biomed. Anal. 2019, 172, 214–222. [Google Scholar] [CrossRef]
  43. Falck, E.; Begrow, F.; Verspohl, E.; Wünsch, B. In vitro and in vivo biotransformation of WMS-1410, a potent GluN2B selective NMDA receptor antagonist. J. Pharm. Biomed. Anal. 2014, 94, 36–44. [Google Scholar] [CrossRef]
  44. Falck, E.; Begrow, F.; Verspohl, E.; Wünsch, B. Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist. J. Pharm. Biomed. Anal. 2014, 88, 96–105. [Google Scholar] [CrossRef]
  45. Schmidt, H.R.; Zheng, S.D.; Gurpinar, E.; Koehl, A.; Manglik, A.; Kruse, A.C. Crystal structure of the human σ1 receptor. Nature 2016, 532, 527. [Google Scholar] [CrossRef]
  46. Massova, I.; Kollman, P.A. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect. Drug Discov. 2000, 18, 113–135. [Google Scholar] [CrossRef]
  47. Kopp, N.; Holtschulte, C.; Börgel, F.; Lehmkuhl, K.; Friedland, K.; Civenni, G.; Laurini, E.; Catapano, C.V.; Pricl, S.; Humpf, H.-U.; et al. Novel σ1 antagonists designed for tumor therapy: Structure—Activity relationships of aminoethyl substituted cyclohexanes. Eur. J. Med. Chem. 2021, 210, 112950. [Google Scholar] [CrossRef]
  48. Holtschulte, C.; Börgel, F.; Westphälinger, S.; Schepmann, D.; Civenni, G.; Laurini, E.; Marson, D.; Catapano, C.V.; Pricl, S.; Wünsch, B. Synthesis of Aminoethyl-Substituted Piperidine Derivatives as σ1 Receptor Ligands with Antiproliferative Properties. ChemMedChem 2022, 17, e202100735. [Google Scholar] [CrossRef]
  49. Wang, Y.; Lin, Q.; Shi, H.; Cheng, D. Fluorine-18: Radiochemistry and Target-Specific PET Molecular Probes Design. Front. Chem. 2022, 10, 884517. [Google Scholar] [CrossRef]
  50. Rong, J.; Haider, A.; Jeppesen, T.E.; Josephson, L.; Liang, S.H. Radiochemistry for positron emission tomography. Nat. Commun. 2023, 14, 3257. [Google Scholar] [CrossRef]
  51. Maisonial-Besset, A.; Funke, U.; Wenzel, B.; Fischer, S.; Holl, K.; Wünsch, B.; Steinbach, J.; Brust, P. Automation of the radiosynthesis and purification procedures for [18F]Fluspidine preparation, a new radiotracer for clinical investigations in PET imaging of σ1 receptors in brain. Appl. Radiat. Isot. 2014, 84, 1–7. [Google Scholar] [CrossRef]
  52. Brust, P.; Deuther-Conrad, W.; Becker, G.; Patt, M.; Donat, C.K.; Stittsworth, S.; Fischer, S.; Hiller, A.; Wenzel, B.; Dukic-Stefanovic, S.; et al. Distinctive in vivo kinetics of the new σ1 receptor ligands (R)-(+)- and (S)-(−)-18F-fluspidine in porcine brain. J. Nucl. Med. 2014, 55, 1730–1736. [Google Scholar] [CrossRef]
  53. Wiese, C.; Maestrup, E.G.; Galla, F.; Schepmann, D.; Hiller, A.; Fischer, S.; Ludwig, F.-A.; Deuther-Conrad, W.; Donat, C.K.; Brust, P.; et al. Comparison of in silico, electrochemical, in vitro and in vivo metabolism of a homologous series of (radio)fluorinated σ1 receptor ligands designed for positron emission tomography. ChemMedChem 2016, 11, 2445–2458. [Google Scholar] [CrossRef]
  54. Baum, E.; Cai, Z.; Bois, F.; Holden, D.; Lin, S.-F.; Lara-Jaime, T.; Kapinos, M.; Chen, Y.; Deuther-Conrad, W.; Fischer, S.; et al. PET imaging evaluation of four σ1 radiotracers in nonhuman primates. J. Nucl. Med. 2017, 58, 982–988. [Google Scholar] [CrossRef] [PubMed]
  55. Phan, V.L.; Urani, A.; Sandillon, F.; Privat, A.; Maurice, T. Preserved sigma1 (sigma1) receptor expression and behavioral efficacy in the aged C57BL/6 mouse. Neurobiol. Aging. 2003, 24, 865–881. [Google Scholar] [CrossRef] [PubMed]
  56. Logan, J.; Fowler, J.S.; Volkow, N.D.; Wolf, A.P.; Dewey, S.L.; Schlyer, D.J.; MacGregor, R.R.; Hitzemann, R.; Bendriem, B.; Gatley, S.J.; et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10, 740–747. [Google Scholar] [CrossRef] [PubMed]
  57. Kranz, M.; Sattler, B.; Deuther-Conrad, W.; Fischer, S.; Hiller, A.; Donat, C.; Wünsch, B.; Steinbach, J.; Sabri, O.; Brust, P. Preclinical dose assessment of (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine, new PET tracers for imaging of σ1 receptors. J. Nucl. Med. 2013, 54 (Suppl. 2), 1028. [Google Scholar]
  58. Kranz, M.; Sattler, B.; Wüst, N.; Deuther-Conrad, W.; Patt, M.; Meyer, P.M.; Fischer, S.; Donat, C.K.; Wünsch, B.; Hesse, S.; et al. Evaluation of the Enantiomer Specific Biokinetics and Radiation Doses of [18F]Fluspidine-A New Tracer in Clinical Translation for Imaging of σ1 Receptors. Molecules 2016, 21, 1164. [Google Scholar] [CrossRef] [PubMed]
  59. Toussaint, M.; Deuther-Conrad, W.; Kranz, M.; Fischer, S.; Ludwig, F.-A.; Juratli, T.A.; Patt, M.; Wünsch, B.; Schackert, G.; Sabri, O.; et al. Sigma-1 receptor Positron Emission Tomography: A new molecular imaging approach using (S)-(−)-[18F]fluspidine in glioblastoma. Molecules 2020, 25, 2170. [Google Scholar] [CrossRef] [PubMed]
  60. Sattler, B.; Kranz, M.; Wuest, N.; Patt, M.; Meyer, P.; Deuther-Conrad, W.; Fischer, S.; Wuensch, B.; Brust, P.; Sabri, O. First-in-man incorporation dosimetry of (S)-(−)-[18F]fluspidine. J. Nucl. Med. 2016, 57 (Suppl. 2), 1022. [Google Scholar]
  61. Wang, Y.M.; Xia, C.Y.; Jia, H.M.; He, J.; Lian, W.W.; Yan, Y.; Wang, W.P.; Zhang, W.K.; Xu, J.K. Sigma-1 receptor: A potential target for the development of antidepressants. Neurochem Int. 2022, 159, 105390. [Google Scholar] [CrossRef]
  62. Meyer, P.; Strauss, M.; Becker, G.; Hesse, S.; Bednasch, K.; Ettrich, B.; Zientek, F.; Rullmann, M.; Wilke, S.; Luthardt, J.; et al. Increased sigma-1 receptor (Sig-1R) binding in the brain of unmedicated patients with acute major depressive disorder (MDD) using the novel Sig-1R-specific radioligand (−)-[18F]Fluspidine and PET. J. Nucl. Med. 2018, 59 (Suppl. 1), 551. [Google Scholar]
  63. Guo, Y.; Zhang, C.; Chen, X.; Liu, X.; Ye, T.; Fo, Y.; Shi, S.; Qu, C.; Liang, J.; Shen, B.; et al. Sigma-1 receptor ligands improves ventricular repolarization-related ion remodeling in rats with major depression disorder. Psychopharmacology 2021, 238, 487–499. [Google Scholar] [CrossRef]
  64. Ludwig, F.-A.; Fischer, S.; Houska, R.; Hoepping, A.; Deuther-Conrad, W.; Schepmann, D.; Patt, M.; Meyer, P.M.; Hesse, S.; Becker, G.-A.; et al. In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine—A Radioligand for Imaging σ1 Receptors With Positron Emission Tomography (PET). Front. Pharmacol. 2019, 10, 534. [Google Scholar] [CrossRef] [PubMed]
  65. Carlsson, M.L. Experimental hypoglutamatergia model for cognitive deficits of schizophrenia: Effects of classical neuroleptics, 5-HT 2Areceptor blocking antipsychotics, the ampakine CX516 and the dopaminergic stabiliser ACR16. Eur. Neuropsychopharmacol. 2002, 12, 167–168. [Google Scholar] [CrossRef]
  66. A. Carlsson Research Ab. New Modulators of Dopamine Neurotransmission. WO/2001/046145; PCT/SE2000/002674, 4 October 2001. [Google Scholar]
  67. Carlsson, M.L.; Carlsson, A.; Nilsson, M. Schizophrenia: From dopamine to glutamate and back. Curr. Med. Chem. 2004, 11, 267–277. [Google Scholar] [CrossRef] [PubMed]
  68. Squitieri, F.; Di Pardo, A.; Favellato, M.; Amico, E.; Maglione, V.; Frati, L. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. J. Cell. Mol. Med. 2015, 19, 2540–2548. [Google Scholar] [CrossRef] [PubMed]
  69. Sahlholm, K.; Sijbesma, J.W.; Maas, B.; Kwizera, C.; Marcellino, D.; Ramakrishnan, N.K.; Dierckx, R.A.; Elsinga, P.H.; van Waarde, A. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology 2015, 232, 3443–3453. [Google Scholar] [CrossRef] [PubMed]
  70. Dreymann, J.; Geva, M.; Ross, J.; Cha, Y.; Kusko, R.; Escalante-Chong, R.; Zeskind, B.; Laifenfeld, B.; Grossman, I.; Hayden, M. Loss of the Sigma-1 receptor disrupts pridopidine-induced gene expression. Neurology 2018, 90, P4.048. [Google Scholar] [CrossRef]
  71. Grachev, I.D.; Meyer, P.M.; Becker, G.A.; Bronzel, M.; Marsteller, D.; Pastino, G.; Voges, O.; Rabinovich, L.; Knebel, H.; Zientek, F.; et al. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: A [18F] fluspidine and [18F] fallypride PET study. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1103–1115. [Google Scholar] [CrossRef] [PubMed]
  72. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef]
  73. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926–935. [Google Scholar] [CrossRef]
  74. Onufriev, A.; Bashford, D.; Case, D.A. Modification of the generalized born model suitable for macromolecules. J. Phys. Chem. 2000, 104, 3712–3720. [Google Scholar] [CrossRef]
  75. Case, D.A.; Aktulga, H.M.; Belfon, K.; Ben-Shalom, I.Y.; Brozell, S.R.; Cerutti, D.S.; Cheatham, T.E., III; Cisneros, G.A.; Cruzeiro, V.W.D.; Darden, T.A.; et al. Amber 2021; University of California: San Francisco, CA, USA, 2021. [Google Scholar]
  76. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef]
Pharmaceuticals 17 00166 g001
Figure 1. σ1 receptor ligands modulating pain perception. The σ1 receptor antagonist S1RA is active in the treatment of neuropathic pain.
Figure 1. σ1 receptor ligands modulating pain perception. The σ1 receptor antagonist S1RA is active in the treatment of neuropathic pain.
Pharmaceuticals 17 00166 g001
Pharmaceuticals 17 00166 g002
Figure 2. σ1 receptor antagonists with antipsychotic potential.
Figure 2. σ1 receptor antagonists with antipsychotic potential.
Pharmaceuticals 17 00166 g002
Pharmaceuticals 17 00166 g003
Figure 3. Donepezil, an acetylcholinesterase inhibitor and σ1 receptor agonist used for the treatment of Alzheimer’s disease.
Figure 3. Donepezil, an acetylcholinesterase inhibitor and σ1 receptor agonist used for the treatment of Alzheimer’s disease.
Pharmaceuticals 17 00166 g003
Pharmaceuticals 17 00166 g004
Figure 4. Clinically used antidepressants with σ1 receptor agonistic activity.
Figure 4. Clinically used antidepressants with σ1 receptor agonistic activity.
Pharmaceuticals 17 00166 g004
Pharmaceuticals 17 00166 g005
Figure 5. σ1 Receptor agonist cutamesine (SA 4503) and derived 18-F-labeled PET tracers [18F]FE-SA 4503 and [18F]FM-SA 4503.
Figure 5. σ1 Receptor agonist cutamesine (SA 4503) and derived 18-F-labeled PET tracers [18F]FE-SA 4503 and [18F]FM-SA 4503.
Pharmaceuticals 17 00166 g005
Pharmaceuticals 17 00166 sch001
Scheme 1. Synthesis of racemic fluspidine rac-2. Reagents and reaction conditions: (a) CH3OH. HC(OCH3)3, TsOH, reflux, 85%. (b) 1. n-BuLi, −95 °C; 2. 1-benzylpiperidin-4-one, −95 °C, then rt; 3. HCl, THF, 66 °C, 11%. (c) Ph3P=CHCO2Et, Cs2CO3, toluene, reflux, 88%. (d) LiAlH4, Et2O, −15 °C, 75%. (e) [(1,3-dioxolan-2-yl)methyl]triphenylphosphonium bromide [(CH2O)2CHCH2PPh3Br], K2CO3, TDA-1 [tris(methoxyethoxyethyl)amine, 95%; (f) n-BuLi, −78 °C, then addition of 1-benzylpiperidin-4-one, −78 °C, then rt, 67%. (g) HCl, 2 M, 37%. (h) NaBH4, CH3CN, 37%. (i) DAST, CH2Cl2, −78 °C, then rt, 56%. (j) TsCl, DMAP, NEt3, CH2Cl2, 17 h, rt, 36%. (k) Bu4NF, THF, 4 h, rt, 80%.
Scheme 1. Synthesis of racemic fluspidine rac-2. Reagents and reaction conditions: (a) CH3OH. HC(OCH3)3, TsOH, reflux, 85%. (b) 1. n-BuLi, −95 °C; 2. 1-benzylpiperidin-4-one, −95 °C, then rt; 3. HCl, THF, 66 °C, 11%. (c) Ph3P=CHCO2Et, Cs2CO3, toluene, reflux, 88%. (d) LiAlH4, Et2O, −15 °C, 75%. (e) [(1,3-dioxolan-2-yl)methyl]triphenylphosphonium bromide [(CH2O)2CHCH2PPh3Br], K2CO3, TDA-1 [tris(methoxyethoxyethyl)amine, 95%; (f) n-BuLi, −78 °C, then addition of 1-benzylpiperidin-4-one, −78 °C, then rt, 67%. (g) HCl, 2 M, 37%. (h) NaBH4, CH3CN, 37%. (i) DAST, CH2Cl2, −78 °C, then rt, 56%. (j) TsCl, DMAP, NEt3, CH2Cl2, 17 h, rt, 36%. (k) Bu4NF, THF, 4 h, rt, 80%.
Pharmaceuticals 17 00166 sch001
Pharmaceuticals 17 00166 sch002
Scheme 2. Synthesis of enantiomerically pure fluspidine enantiomers (R)-2 and (S)-2 by chiral resolution of racemic tosylate 19. Reagents and reaction conditions: (a) Daicel® Chiralpak IB, 5 µm, 250 mm/20 mm. Eluent, isohexane:ethanol, 100:2; flow rate, 10.0 mL/min. (R)-19: tR = 26–27 min, 98.2%ee. (S)-19: tR = 28–36 min. 97.8%ee. (b) Bu4NF, THF, rt, 3.5 h, 69%, 99.6%ee. (c) Bu4NF, THF, rt, 17 h, 80%, 96.4%ee.
Scheme 2. Synthesis of enantiomerically pure fluspidine enantiomers (R)-2 and (S)-2 by chiral resolution of racemic tosylate 19. Reagents and reaction conditions: (a) Daicel® Chiralpak IB, 5 µm, 250 mm/20 mm. Eluent, isohexane:ethanol, 100:2; flow rate, 10.0 mL/min. (R)-19: tR = 26–27 min, 98.2%ee. (S)-19: tR = 28–36 min. 97.8%ee. (b) Bu4NF, THF, rt, 3.5 h, 69%, 99.6%ee. (c) Bu4NF, THF, rt, 17 h, 80%, 96.4%ee.
Pharmaceuticals 17 00166 sch002
Pharmaceuticals 17 00166 sch003
Scheme 3. Synthesis of enantiomerically pure alcohols (R)-18 and (S)-18 by enantioselective reduction of α,β-unsaturated ester 23. Reagents and reaction conditions: (a) Sonogashira coupling—PdCl2(PPh3)2, CuI, NEt3, THF, rt, 15 h, 47%. (b) 1. n-BuLi, THF, −78 °C; 2. 1-benzylpiperidin-4-one, 62%. (c) 1. NaBH4, 0.01 equiv. chiral co-complex (R,R)-24, CH3OH/CH2Cl2 1:1, 0 °C → rt, 30 min; 2. LiAlH4, Et2O, yield 63%, 95.6%ee. (d) 1. NaBH4, 0.01 equiv. chiral co-complex (S,S)-24, CH3OH/CH2Cl2 1:1, 0 °C → rt, 30 min; 2. LiAlH4, Et2O, yield 82%, 97.2%ee. (e) TsCl, NEt3, DMAP, CH2Cl2, 17 h, (R)-19 (96.2%ee), (S)-19 (96.4%ee).
Scheme 3. Synthesis of enantiomerically pure alcohols (R)-18 and (S)-18 by enantioselective reduction of α,β-unsaturated ester 23. Reagents and reaction conditions: (a) Sonogashira coupling—PdCl2(PPh3)2, CuI, NEt3, THF, rt, 15 h, 47%. (b) 1. n-BuLi, THF, −78 °C; 2. 1-benzylpiperidin-4-one, 62%. (c) 1. NaBH4, 0.01 equiv. chiral co-complex (R,R)-24, CH3OH/CH2Cl2 1:1, 0 °C → rt, 30 min; 2. LiAlH4, Et2O, yield 63%, 95.6%ee. (d) 1. NaBH4, 0.01 equiv. chiral co-complex (S,S)-24, CH3OH/CH2Cl2 1:1, 0 °C → rt, 30 min; 2. LiAlH4, Et2O, yield 82%, 97.2%ee. (e) TsCl, NEt3, DMAP, CH2Cl2, 17 h, (R)-19 (96.2%ee), (S)-19 (96.4%ee).
Pharmaceuticals 17 00166 sch003
Pharmaceuticals 17 00166 g006
Figure 6. Metabolites formed by incubation of 2, (R)-2, and (S)-2 with rat liver microsomes and NADPH [36].
Figure 6. Metabolites formed by incubation of 2, (R)-2, and (S)-2 with rat liver microsomes and NADPH [36].
Pharmaceuticals 17 00166 g006
Pharmaceuticals 17 00166 g007
Figure 7. Details of (R)-fluspidine (A) and (S)-fluspidine (B) in the binding pocket of the σ1 receptor. Compounds are shown as atom-colored sticks-and-balls (C, grey, N, blue, O, red, F, green), while the side chains of the protein residues mainly interacting with the ligands are depicted as colored sticks and labeled. Hydrogen atoms, water molecules, ions, and counterions are omitted for clarity.
Figure 7. Details of (R)-fluspidine (A) and (S)-fluspidine (B) in the binding pocket of the σ1 receptor. Compounds are shown as atom-colored sticks-and-balls (C, grey, N, blue, O, red, F, green), while the side chains of the protein residues mainly interacting with the ligands are depicted as colored sticks and labeled. Hydrogen atoms, water molecules, ions, and counterions are omitted for clarity.
Pharmaceuticals 17 00166 g007
Pharmaceuticals 17 00166 g008
Figure 8. (A) Per-residue binding free energy decomposition of the main interacting residues of the σ1/(R)-fluspidine (firebrick) and σ1/(S)-fluspidine (light sea green) complexes. Zoomed details of the interaction between the F-atom and T202 hydroxy group in σ1/(R)-fluspidine (B) and σ1/(S)-fluspidine (C) complexes. Compounds are shown as atom-colored sticks-and-balls (C, grey, N, blue, O, red, F, green).
Figure 8. (A) Per-residue binding free energy decomposition of the main interacting residues of the σ1/(R)-fluspidine (firebrick) and σ1/(S)-fluspidine (light sea green) complexes. Zoomed details of the interaction between the F-atom and T202 hydroxy group in σ1/(R)-fluspidine (B) and σ1/(S)-fluspidine (C) complexes. Compounds are shown as atom-colored sticks-and-balls (C, grey, N, blue, O, red, F, green).
Pharmaceuticals 17 00166 g008
Pharmaceuticals 17 00166 sch004
Scheme 4. The automated radiosynthesis of enantiomerically pure fluspidine enantiomers (R)-[18F]2 and (S)-[18F]2. Reagents and reaction conditions: (a) [18F]KF, Kryptofix-2.2.2, 2.5–3 mg tosylate precursor (R)-19 or (S)-19, CH3CN (1 mL), 85 °C, 25 min, radiochemical yield (RCY) 35–45% (N = 10), radiochemical purity (RCP) > 99.6%, molar activity (Am) 150–350 GBq/µmol.
Scheme 4. The automated radiosynthesis of enantiomerically pure fluspidine enantiomers (R)-[18F]2 and (S)-[18F]2. Reagents and reaction conditions: (a) [18F]KF, Kryptofix-2.2.2, 2.5–3 mg tosylate precursor (R)-19 or (S)-19, CH3CN (1 mL), 85 °C, 25 min, radiochemical yield (RCY) 35–45% (N = 10), radiochemical purity (RCP) > 99.6%, molar activity (Am) 150–350 GBq/µmol.
Pharmaceuticals 17 00166 sch004
Pharmaceuticals 17 00166 g009
Figure 9. Fractions of unchanged PET tracer and radiometabolites in the plasma of various species determined at 30 and 60 min following intravenous administration of the corresponding radioligand [54,55,56,57,58,59,60,61].
Figure 9. Fractions of unchanged PET tracer and radiometabolites in the plasma of various species determined at 30 and 60 min following intravenous administration of the corresponding radioligand [54,55,56,57,58,59,60,61].
Pharmaceuticals 17 00166 g009
Pharmaceuticals 17 00166 g010
Figure 10. Fractions of unchanged PET tracer and radiometabolites in the plasma and urine of humans determined at different times following the intravenous administration of (S)-[18F]2.
Figure 10. Fractions of unchanged PET tracer and radiometabolites in the plasma and urine of humans determined at different times following the intravenous administration of (S)-[18F]2.
Pharmaceuticals 17 00166 g010
Pharmaceuticals 17 00166 g011
Figure 11. Main radiometabolites formed in humans after administration of (S)-[18F]2.
Figure 11. Main radiometabolites formed in humans after administration of (S)-[18F]2.
Pharmaceuticals 17 00166 g011
Pharmaceuticals 17 00166 g012
Figure 12. Pridopidine interacting with σ1 receptors.
Figure 12. Pridopidine interacting with σ1 receptors.
Pharmaceuticals 17 00166 g012
Table 1. Spirocyclic piperidines with fluoroalkyl side chains.
Table 1. Spirocyclic piperidines with fluoroalkyl side chains.
Pharmaceuticals 17 00166 i001
Compd.nRKi(σ1)
(nM)		Ki(σ2)
(nM)		σ1/σ2 Selectivity
11-CH2C6H50.74550743
22-CH2C6H50.597851331
33-CH2C6H51.4837598
44-CH2C6H51.2489408
52-CH2C6H4-p-F0.57481844
62-CH2C6H110.715780
72-CH(CH3)C6H51.0>1 µM>1000
82n-butyl3.9878225
92n-octyl151187.9
102-CH2CH=C(CH3)21.5>1 µM667
Table 2. Pharmacokinetic properties of spirocyclic piperidines 1–4 with homologous fluoroalkyl side chain.
Table 2. Pharmacokinetic properties of spirocyclic piperidines 1–4 with homologous fluoroalkyl side chain.
Pharmaceuticals 17 00166 i002
Compd.nKi(σ1)
(nM)		logD7.4 (a)
Micro Shake Flask		logD7.2 (b)
PET Tracer		Plasma Protein Binding (%)In Vitro Metabolism—Intact Compd. after 90 min (%)
110.742.80 ± 0.042.39 ± 0.0484 ± 0.553 ± 3.9
220.593.33 ± 0.072.57 ± 0.3288 ± 0.434 ± 8.8
331.43.60 ± 0.122.78 ± 0.0691 ± 0.433 ± 7.9
441.23.71 ± 0.143.11 ± 0.1495 ± 0.328 ± 4.5
(a) logD7.4: n-octanol/MOPS buffer pH 7.4, determined by LC-MS. (b) logD7.2: n-octanol/phosphate buffered saline pH 7.2, determined by measuring the radioactivity in both layers.
Table 3. Radiosynthetic data of the homologous PET tracers [18F]1–[18F]4 obtained in non-automated synthesis.
Table 3. Radiosynthetic data of the homologous PET tracers [18F]1–[18F]4 obtained in non-automated synthesis.
Pharmaceuticals 17 00166 i003
PET TracerReaction Conditions (a)RCYni (b) (%)RCYfi (c)
(%)		RCP (d)
(%)		Am (e) (GBq/µmol)Time (f)
(min)
[18F]1DMSO, 150 °C,67–8638–50>99.1173–41280–100
(n = 1)10–15 min(N = 4)(N = 3)
[18F]2CH3CN, 85 °C,60–7035–45>99.6150–35090–120
(n = 2)25 min(N = 10)(N = 6)
[18F]3CH3CN, 85 °C,60–7035–48>99.5150–23890–120
(n = 3)30 min(N = 11)(N = 7)
[18F]4CH3CN, 83 °C,60–8845–51>98.6201–52890–120
(n = 4)20 min(N = 8)(N = 7)
(a) 2.5–3 mg tosylate precursor. (b) RCYni: radiochemical yield (not isolated). (c) RCYfi: radiochemical yield (final). (d) RCP: radiochemical purity. (e) Am: molar activity. (f) Complete synthesis time until final formulation. Parentheses include the number N of experiments.
Table 4. Data obtained in the automated radiosynthesis of the racemic and the enantiomerically pure PET tracers[18F]2, (R)-[18F]2 and (S)-[18F]2 [51,52].
Table 4. Data obtained in the automated radiosynthesis of the racemic and the enantiomerically pure PET tracers[18F]2, (R)-[18F]2 and (S)-[18F]2 [51,52].
Pharmaceuticals 17 00166 i004
PET TracerReaction Conditions (a)RCYfi (b)RCP (c)Am (d) (GBq/µmol)Time (e)
(%)(%)(min)
[18F]2CH3CN, 85 °C,37 ± 899.4 ± 0.5177 ± 5259 ± 4
25 min(N = 9)(N = 11)(N = 5)(N = 8)
(R)-[18F]2 CH3CN, 85 °C,35–45>99650–87070
15 min
(S)-[18F]2 CH3CN, 85 °C,35–45>99650–87070
15 min
(a) K[18F]F, K2.2.2, 2.5–3 mg tosylate precursor 19, (R)-19 and (S)-19 using the TRACERlab FX FN synthesis module. (b) RCYfi: radiochemical yield (final). (c) RCP: radiochemical purity. (d) Am: molar activity. (e) Complete synthesis time until final formulation. Parentheses include the number of experiments.
Table 5. Summary of the distribution pattern of rac-[18F]2, (S)-[18F]2, and (R)-[18F]2 binding sites in the brains of mice, piglets and rhesus monkeys.
Table 5. Summary of the distribution pattern of rac-[18F]2, (S)-[18F]2, and (R)-[18F]2 binding sites in the brains of mice, piglets and rhesus monkeys.
SpeciesParameter
(Experimental Details)		RadiotracerBrain Region (Values)
Mouse [32]Ratio of activity concentration (target region vs. olfactory bulb at 45 min p.i.; N = 1)rac-[18F]2Facial nucleus (4.69), cerebellum (1.75), superficial grey layer of superior colliculus (1.57), cortex (1.45), thalamus (1.24), hippocampus (1.21), striatum (1.11)
Piglet [52]VT in mL/g (Logan plot; baseline conditions; N = 3)(S)-[18F]2Midbrain (15.4), colliculi (15.2), cerebellum (14.8), thalamus (14.1), striatum (13.5), hippocampus (13.5), cortex (9.8–13.1)
(R)-[18F]2Cerebellum (140), midbrain (132), colliculi (123), thalamus (106), striatum (100), hippocampus (95.2), cortex (67.8–98.4)
Rhesus monkey [54]VT in mL/g (1-Tissue compartment model;
baseline conditions; N = 1)		(S)-[18F]2Cortex (14.6–19.6), hippocampus (16.4), putamen (14.9), amygdala (14.6), caudate (13.5), cerebellum (13.6), caudate (13.5), thalamus (12.2)
(R)-[18F]2Cortex (174–291), putamen (199), hippocampus (193), caudate (181), cerebellum (175), amygdala (153), thalamus (128)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ludwig, F.-A.; Laurini, E.; Schmidt, J.; Pricl, S.; Deuther-Conrad, W.; Wünsch, B. [18F]Fluspidine—A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System. Pharmaceuticals 2024, 17, 166. https://doi.org/10.3390/ph17020166

AMA Style

Ludwig F-A, Laurini E, Schmidt J, Pricl S, Deuther-Conrad W, Wünsch B. [18F]Fluspidine—A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System. Pharmaceuticals. 2024; 17(2):166. https://doi.org/10.3390/ph17020166

Chicago/Turabian Style

Ludwig, Friedrich-Alexander, Erik Laurini, Judith Schmidt, Sabrina Pricl, Winnie Deuther-Conrad, and Bernhard Wünsch. 2024. "[18F]Fluspidine—A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System" Pharmaceuticals 17, no. 2: 166. https://doi.org/10.3390/ph17020166

APA Style

Ludwig, F. -A., Laurini, E., Schmidt, J., Pricl, S., Deuther-Conrad, W., & Wünsch, B. (2024). [18F]Fluspidine—A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System. Pharmaceuticals, 17(2), 166. https://doi.org/10.3390/ph17020166

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop